Enlivex Therapeutics: Funding, Investors & Team (Sep 2026)
Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn's Disease, and other autoimmune and inflammatory disorders. The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity. Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells.
Enlivex Therapeutics has raised $228M across 3 funding rounds on record, the most recent an undisclosed round of $212M announced in Nov 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Enlivex Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Enlivex Therapeutics Funding Rounds
Enlivex Therapeutics raised $1.1M in an undisclosed round announced in May 2021.
3 years later, an undisclosed round of $15.0M was announced in May 2024.
1.5 years later, an undisclosed round of $212M was announced in Nov 2025.
Enlivex Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Enlivex Therapeutics Funding Compared to Other Biotechnology Startups
Enlivex Therapeutics' latest round of $212M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Enlivex Therapeutics in Biotechnology and Ness Ziona
Companies Similar to Enlivex Therapeutics
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
Enlivex Therapeutics Funding FAQs
What does Enlivex Therapeutics do?
Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn's Disease, and other autoimmune and inflammatory disorders. The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity. Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells.
How much funding has Enlivex Therapeutics raised?
Enlivex Therapeutics has raised $228M across 3 rounds on record. The most recent is an undisclosed round of $212M announced in Nov 2025.
When did Enlivex Therapeutics last raise funding?
Enlivex Therapeutics' most recent funding round on record is an undisclosed round of $212M, announced in Nov 2025.
Who founded Enlivex Therapeutics?
FundedIQ lists Dror Mevorach (Founder) at Enlivex Therapeutics.
Who is the CEO of Enlivex Therapeutics?
Oren Hershkovitz is listed as CEO at Enlivex Therapeutics.
Where is Enlivex Therapeutics headquartered?
Enlivex Therapeutics is based in Ness Ziona, Hamerkaz, Israel.
How many employees does Enlivex Therapeutics have?
Enlivex Therapeutics is in the 11-50 employee band.
How does Enlivex Therapeutics' funding compare to other Biotechnology startups?
Enlivex Therapeutics' latest round of $212M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Enlivex Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Enlivex Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.